Kodiak Sciences (NASDAQ:KOD) Stock Price Up 5.2% After Insider Buying Activity

Shares of Kodiak Sciences Inc. (NASDAQ:KOD) were up 5.2% during trading on Thursday following insider buying activity. The stock traded as high as $104.00 and last traded at $99.6990. 974,916 shares changed hands during trading, a decline of 11% from the average session volume of 1,089,432 shares. The stock had previously closed at $94.80.

Specifically, Director Bros. Advisors Lp Baker bought 807,840 shares of Kodiak Sciences stock in a transaction dated Monday, September 28th. The shares were purchased at an average cost of $72.57 per share, with a total value of $58,624,948.80. Following the completion of the purchase, the director owned 19,121,134 shares of the company’s stock, valued at approximately $1,387,620,694.38. This represents a 4.41% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker purchased 418,323 shares of the company’s stock in a transaction that occurred on Monday, September 28th. The stock was acquired at an average cost of $83.58 per share, with a total value of $34,963,436.34. Following the purchase, the director directly owned 19,515,907 shares of the company’s stock, valued at $1,631,139,507.06. This trade represents a 2.19% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In related news, Director Bros. Advisors Lp Baker purchased 33,726 shares of the business’s stock in a transaction that occurred on Tuesday, September 29th. The shares were acquired at an average price of $85.05 per share, for a total transaction of $2,868,396.30. Following the completion of the acquisition, the director directly owned 20,191,214 shares in the company, valued at approximately $1,717,262,750.70. The trade was a 0.17% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Analyst Ratings Changes

KOD has been the subject of several research reports. The Goldman Sachs Group restated a “neutral” rating and issued a $103.00 price objective on shares of Kodiak Sciences in a report on Wednesday. Wall Street Zen downgraded shares of Kodiak Sciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 26th. HC Wainwright raised their price objective on shares of Kodiak Sciences from $58.00 to $96.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kodiak Sciences in a report on Friday, July 10th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $112.00 target price on shares of Kodiak Sciences in a research report on Monday. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $100.43.

Key Stories Impacting Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Strong clinical results remain the primary catalyst. Phase 3 DAYBREAK data reportedly showed Zenkuda and KSI-501 meeting key endpoints against Eylea in wet age-related macular degeneration. Kodiak is advancing Zenkuda toward a BLA filing, strengthening the potential commercial opportunity in the retinal-drug market. Positive wet AMD data article
• Positive Sentiment: Analyst support and trading activity are increasing. HC Wainwright maintained a Buy rating and raised its price target to $96, while lifting its FY2029 EPS forecast to $1.76 from $0.18 and its FY2030 estimate to $5.81 from $3.04. The analyst also expects Kodiak to move from losses toward profitability in later years. Unusually high volume following the analyst upgrade indicates strong investor attention. Analyst upgrade and trading volume article
• Positive Sentiment: Insider buying provides an additional confidence signal. Director Bros. Advisors LP Baker reported purchases totaling approximately 1.94 million shares for about $157 million on September 28–29, materially increasing an already large ownership position. SEC insider purchase filing
• Neutral Sentiment: Analyst estimates were mixed in the near term. HC Wainwright slightly increased its projected FY2028 loss but reduced its FY2027 loss estimate only modestly, while significantly improving forecasts for FY2029 and FY2030.
• Negative Sentiment: Risks are elevated after the sharp run-up. Kodiak has no current revenue, remains cash-burning and may need to issue shares, creating dilution risk. Heavy put-option buying signals that some traders are hedging against volatility or a pullback. Kodiak valuation and financing risks article

Kodiak Sciences Stock Up 6.6%

The firm has a market cap of $6.35 billion, a PE ratio of -24.15 and a beta of 2.18. The stock’s fifty day simple moving average is $41.32 and its two-hundred day simple moving average is $38.77.

Kodiak Sciences (NASDAQ:KOD) last released its earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.09). On average, equities research analysts anticipate that Kodiak Sciences Inc. will post -3.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. V Square Quantitative Management LLC purchased a new stake in shares of Kodiak Sciences in the first quarter worth $26,000. Westfuller Advisors LLC bought a new position in Kodiak Sciences in the 1st quarter worth about $26,000. EverSource Wealth Advisors LLC grew its position in Kodiak Sciences by 1,221.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after purchasing an additional 916 shares during the last quarter. KBC Group NV purchased a new stake in Kodiak Sciences during the 1st quarter valued at about $39,000. Finally, E Fund Management Co. Ltd. bought a new stake in Kodiak Sciences during the 2nd quarter valued at about $228,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.